Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
27 September 2022 - 2:00AM
Guerbet obtains one million euros of public funding from Bpifrance
(France 2030 investment plan) for a project developing artificial
intelligence for the early detection of pancreatic cancer
Guerbet obtains one million euros of
public funding from Bpifrance (France 2030 investment plan) for a
project developing artificial intelligence for the early detection
of pancreatic cancer
Villepinte, 26
September 2022 – 18:00: Guerbet
(GBT) obtains one million euros of public funding through a call
for projects concerning the acceleration strategy in digital health
via the France 2030 investment plan. The early diagnosis of
pancreatic cancer is a major public health concern. The
presentation of the work of Guerbet's Artificial Intelligence (AI)
research team, which could potentially offer a promising response
to a medical need, convinced the jury to support this project with
public funding
Pancreatic cancer represents 496,000 cases per
year, of which 14,500 are in France and 56,700 in the USAi. The
number of patients suffering from this disease has doubled over the
last 25 years. The mortality rate of patients is high with survival
ranging from one to five years depending on the stage of the
disease at the time of diagnosisii. By 2040, pancreatic cancer will
constitute the third cause of death by cancer in the EUiii and the
fourth in the USAiv.
“Today, far too many patients are
diagnosed at a late stage due to the silent progression of the
disease and the huge difficulty in distinguishing the early stages
in routine medical imaging. Artificial Intelligence offers a new
tool which could support radiologists in their mission”.
Professor Vuillerme, Hospital Practitioner, Associate Professor at
the Paris-Cité University, Radiologist
Unfortunately, few therapeutic options are
currently available to treat pancreatic cancer. Surgery is the only
treatment which may potentially cure the disease, but it can only
be considered during the early stages of the diseasev. Less than
20% of patients are eligible for surgery, as a result of the late
detectionsvi.
The early stages of pancreatic cancer are often
asymptomatic, and the detection is often fortuitous and late.
“Earlier detection would enable more patients to be eligible for
surgery, which could lead to considerably higher survival
rates.6,vii
CT scans of the pancreas are often difficult to
interpret for radiologists who are not specialized in digestive
diseasesviii. With effective algorithms and solutions already under
development for the detection of liver and prostate cancers,
Guerbet continues to innovate and will thus potentially increase
chance of surviving from this “silent” cancer. The solution
developed by Guerbet will permit the automatic analysis of scanners
and will provide radiologists with an alert when pancreatic cancer
is suspected from the very first stages of the disease.
“Every year the lives of thousands of
families are disrupted by the announcement of a pancreatic cancer
for which no one is prepared! Since 2016, Espoir Pancréas has been
fighting for early detection of pancreatic cancer. We truly hope
that in the future Artificial Intelligence solutions will offer
improved diagnosis and prognosis for patients suffering from these
cancers.” Philippe François-Steininger, Chairman of the
association Espoir Pancréas
Connections with the project’s clinical partners
are already in progress and certain French and international
partnerships are already under discussion. Furthermore, a large
database has already been constituted.
This financial support will enable the
acceleration of the development of the solution and the recognition
provides great incentive for the project team.
“BPI’s financial support is a great
acknowledgement of the quality of Guerbet’s work in the field of
Artificial Intelligence at the service of healthcare. This support
will enable the development of the project to be accelerated and
give it the dimension necessary to develop a commercial product by
2025. We are convinced that these promising Artificial Intelligence
solutions will contribute to the improvement of the diagnosis of
cancers with a high mortality rate. Guerbet is thus demonstrating
once again the ability to provide professionals with a major
innovation for the benefit of patients.” François Nicolas,
Vice-President in charge of R&D at Guerbet
About France 2030
The France 2030 investment plan:
- Translates a dual ambition: to sustainably
transform key sectors of our economy (energy, automobile,
aeronautics and space) by technological innovation, and position
France not only as an actor but as a leader in tomorrow’s world.
From fundamental research to the emergence of an idea until the
production of a new product or service, France 2030 supports the
entire life cycle from innovation until its industrialization.
- Is unique in its scope: €54 billion will be
invested so that our companies, our universities and our research
organizations fully succeed with their transitions in these
strategic branches. What is at stake is to enable them to respond
in a competitive manner to the ecological and attractiveness
challenges of tomorrow’s world and unveil the future champions of
our industries of excellence. France 2030 is defined by two
transverse objectives, consisting of devoting 50% of its
expenditure to decarbonization of the economy and 50% to emerging
actors full of innovation without expenditure unfavorable to the
environment (in the sense of the Do No Significant Harm
principle).
- Is implemented collectively: thought through
and deployed in conjunction with local and European economic and
academic actors to determine the strategic guidelines and flagship
actions thereof. Project innovators are invited to submit their
dossier via open, demanding and selective procedures to benefit
from State accompaniment.
- Is coordinated by the General Secretariat for
investment on behalf of the Prime Minister and implemented
by the Ecological Transition Agency (ADEME), the National Research
Agency (ANR), Bpifrance and the Caisse des Dépôts et Consignations
(CDC).
More information: france2030.gouv.fr | @SGPI_Avenir
i Globocan 2020
ii
https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis
iii
https://www.openaccessgovernment.org/tackling-the-burden-of-pancreatic-cancer-in-europe/98097/
iv Rahib, et al. JAMA Network Open. 2021;4(4):e214708
v PanCAN’s Pancreatic Cancer Early Detection Initiative –
Pancreatic Cancer Action Network
vi
https://healthcare-in-europe.com/en/news/pancreatic-cancer-current-challenges-future-direction.html
vii Chari et al. Early Detection of Sporadic Pancreatic Cancer.
Pancreas - Volume 44, Number 5, July 2015
viii Levy et al. Un plaidoyer pour la pancréatologie,
HEPATO-GASTRO et Oncologie digestive. vol. 24 n8 4, avril 2017
About Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. That is our purpose. We are a
global leader in medical imaging, offering a comprehensive range of
pharmaceutical products, medical devices, and digital and AI
solutions for diagnostic and interventional imaging. As pioneers in
contrast agents for 95 years, with more than 2,600 employees
worldwide, we continuously innovate and devote 9% of our revenue to
research and development in four centers in France, Israel, and the
United States. Guerbet (GBT) is listed on Euronext Paris (segment
B – mid caps) and generated €732 million in revenue in 2021. For
more information, please visit www.guerbet.com.
Contacts:
GuerbetClaire Lauvernier, Group Communication Director
+33.6.79.52.11.88 / claire.lauvernier@guerbet.com
ActifinMathias Jordan, Media Relations +33.1.56.88.11.26 /
mjordan@actifin.fr
Guerbet (EU:GBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2023 to Oct 2024